Limitations, agreements, and source contact

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia · Source last updated 2015-01-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

point Of Contact

email

mmcdev1@jhmi.edu

organization

Sidney Kimmel Comprehensive Cancer Center

phone

410-955-9175

title

Michael McDevitt, MD PhD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice